| Health / Medical Topics |
Zanolimumab
A human IgG1k monoclonal antibody against the CD4 receptor on T-lymphocytes, with potential antineoplastic and immunosuppressing activities. Zanolimumab targets and binds to the CD4 receptor on certain T-cells thereby preventing the interaction between the CD4 receptor and the major histocompatibility complex class II molecule. This prevents activation of CD4 positive T cells. In addition, zanolimumab is able to induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD4-expressing tumor cells. CD4, a receptor located on a subset of T-lymphocytes, is upregulated in T-cell lymphomas. (NCI Thesaurus)
YOU MAY ALSO LIKE
A drug used to prevent and to treat influenza virus infections. It blocks the release of the virus from infected cells. It…
A country in southern Africa, east of Angola and north of Zimbabwe.
A fully human IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR is a cell surface receptor…
A drug used with other drugs to treat colorectal cancer that has spread to other parts of the body and has…
A nonbenzodiazepine from the pyrazolopyrimidine class with hypnotic, sedative, anxiolytic, and muscle relaxant properties. Zaleplon interacts with the gamma-aminobutyric acid (GABA) -A…
A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zalcitabine preferentially inhibits the gamma form of DNA polymerase present in tumor…
